Aleksandra Wosztyl

Aleksandra Wosztyl

Auto-generated profile, based on publicly available information

Aleksandra Wosztyl

The University of Texas Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DCDailu Chen
Dailu Chen
SBSofia Bali
Sofia Bali
RSRuhar Singh
Ruhar Singh
AWAleksandra Wosztyl
Aleksandra Wosztyl
VMVishruth Mullapudi
Vishruth Mullapudi
LJLukasz A. Joachimiak
Lukasz A. Joachimiak
Amyloid deposition of the microtubule-associated protein tau is associated with neurodegenerative diseases. In frontotemporal dementia with abnormal tau (FTD-tau), missense mutations in tau enhance its aggregation propensity. Here we describe the structural mechanism for how an FTD-tau S320F mutation drives spontaneous aggregation, integrating data from in vitro, in silico and cellular experiments. We find that S320F stabilizes a local hydrophobic cluster which allosterically exposes the 306VQIVYK311 amyloid motif; identify a suppressor mutation that destabilizes S320F-based hydrophobic clustering reversing the phenotype in vitro and in cells; and computationally engineer spontaneously aggregating tau sequences through optimizing nonpolar clusters surrounding the S320 position. We uncover a mechanism for regulating tau aggregation which balances local nonpolar contacts with long-range interactions that sequester amyloid motifs. Understanding this process may permit control of tau aggregation into structural polymorphs to aid the design of reagents targeting disease-specific tau conformations.

27 October 2022 in The Journal of Physical Chemistry B
Verified
Journal Article
Open access
AWAleksandra Wosztyl
Aleksandra Wosztyl
KKKrzysztof Kuczera
Krzysztof Kuczera
Robert SzoszkiewiczRobert Szoszkiewicz
Robert Szoszkiewicz
In this paper we derive analytically from molecular dynamics (MD) simulations the friction coefficients related to conformational transitions within several model peptides with α-helical structures. We study a series of alanine peptides with various length from ALA5 to ALA21 as well as their two derivatives, the (AAQAA)3 peptide and a 13-residue KR1 peptide that is a derivative of the (AAQAA)2 peptide with the formula GN(AAQAA)2G. We use two kinds of approaches to derive their friction coefficients. In the local approach, friction associated with fluctuations of single hydrogen bonds are studied. In the second approach, friction coefficients associated with a folding transitions within the studied peptides are obtained. In both cases, the respective friction coefficients differentiated very well the subtle structural changes between studied peptides and compared favorably to experimentally available data.

14 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSofia Bali
Sofia Bali
RSRuhar Singh
Ruhar Singh
PWPawel M. Wydorski
Pawel M. Wydorski
AWAleksandra Wosztyl
Aleksandra Wosztyl
VPValerie A. Perez
Valerie A. Perez
LJLukasz A. Joachimiak
Lukasz A. Joachimiak
The microtubule-associated protein tau is implicated in neurodegenerative diseases characterized by amyloid formation. Mutations associated with frontotemporal dementia increase tau aggregation propensity and disrupt its endogenous microtubule-binding activity. The structural relationship between aggregation propensity and biological activity remains unclear. We employed a multi-disciplinary approach, including computational modeling, NMR, cross-linking mass spectrometry, and cell models to design tau sequences that stabilize its structural ensemble. Our findings reveal that substitutions near the conserved, PGGG, beta-turn motif can modulate local conformation, more stably engaging in interactions with the 306VQIVYK311 amyloid motif to decrease aggregation in vitro and in cells. Designed tau sequences maintain microtubule binding and explain why 3R isoforms of tau exhibit reduced pathogenesis over 4R isoforms. We propose a simple mechanism to reduce the formation of pathogenic species while preserving biological function, offering insights for therapeutic strategies aimed at reducing protein misfolding in neurodegenerative diseases.

3 November 2026 in Advanced Science
Verified
Journal Article
Open access
CRCyrus T. Rastegar
Cyrus T. Rastegar
JPJulia Powell
Julia Powell
AWAleksandra Wosztyl
Aleksandra Wosztyl
GDGuillaume David
Guillaume David
KJKlaudia Jaczynska
Klaudia Jaczynska
JRJosep Rizo
Josep Rizo
Doc2s modulate neurotransmitter release through interactions with Munc13‐1, SNAREs, lipids, and Ca 2+ , which involve the Doc2 C 2 domains and Munc13‐interacting domain (MID). However, it is unclear how these interactions are coupled, how Doc2s bind to Munc13‐1, and how they bind to the SNAREs. Here we determined the cryo‐electron microscopy structure of a Doc2B‐Munc13‐1 complex aided by an AI‐designed Munc13‐1 binder, revealing how Doc2B MID binds to a Munc13‐1 hydrophobic pocket essential for opening syntaxin‐1 and explaining why Doc2B inhibits SNARE assembly. NMR and fluorescence spectroscopy show that Doc2B MID binds lipids and that MID‐lipid and MID‐Munc13‐1 interactions are mutually exclusive, suggesting that membrane binding helps release the inhibition of Munc13‐1. NMR shows that Doc2B binds to the SNARE complex via two helices of C 2 B. Based on these results and liposome fusion assays, we propose a working model whereby: 1. Doc2B MID‐Munc13‐1 interactions facilitate synergistic binding of both proteins to the plasma membrane, with the MID inhibiting Munc13‐1. 2. Membrane binding facilitates MID‐lipid interactions that transiently relieve the inhibition of Munc13‐1, allowing SNARE complex assembly. 3. Doc2B binding to the SNARE complex inhibits neurotransmitter release but generates a primed state that mediates neurotransmitter release by an as‐yet‐unknown mechanism.

22 August 2022 in Research Square
Verified
Preprint
Open access
PDF file
DCDailu Chen
Dailu Chen
AWAleksandra Wosztyl
Aleksandra Wosztyl
VMVishruth Mullapudi
Vishruth Mullapudi
SBSofia Bali
Sofia Bali
JVJaime Vacquer-Alicea
Jaime Vacquer-Alicea
LJLukasz Joachimiak
Lukasz Joachimiak
Amyloid deposition of the microtubule-associated protein tau is a unifying theme in a multitude of neurodegenerative diseases. Disease-associated missense mutations in tau are associated with frontotemporal dementia (FTD) and enhance tau aggregation propensity. However, the molecular mechanism of how mutations in tau promote tau assembly into amyloids remains obscure. There is a need to understand how tau folds into pathogenic conformations to cause disease. Here we describe the structural mechanism for how an FTD-tau S320F mutation drives spontaneous aggregation. We use recombinant protein and synthetic peptide systems, computational modeling, cross-linking mass spectrometry, and cell models to investigate the mechanism of spontaneous aggregation of the S320F FTD-tau mutant. We discover that the S320F mutation drives the stabilization of a local hydrophobic cluster which allosterically exposes the 306VQIVYK311 amyloid motif. We identify a suppressor mutation that reverses the S320F aggregation phenotype through the reduction of S320F-based hydrophobic clustering in vitro and in cells. Finally, we use structure-based computational design to engineer rapidly aggregating tau sequences by optimizing nonpolar clusters in proximity to the S320 site revealing a new principle that governs the regulation of tau aggregation. We uncover a mechanism for regulating aggregation that balances transient nonpolar contacts within local protective structures or in longer-range interactions that sequester amyloid motifs. The introduction of a pathogenic mutation redistributes these transient interactions to drive spontaneous aggregation. We anticipate deeper knowledge of this process will permit control of tau aggregation into discrete structural polymorphs to aid design of reagents that can detect disease-specific tau conformations.

16 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
LJLukasz Joachimiak
Lukasz Joachimiak
SBSofia Bali
Sofia Bali
RSRuhar Singh
Ruhar Singh
PWPawel Wydorski
Pawel Wydorski
AWAleksandra Wosztyl
Aleksandra Wosztyl
JRJosep Rizo
Josep Rizo
The microtubule-associated protein tau is implicated in neurodegenerative diseases characterized by amyloid formation. Mutations associated with frontotemporal dementia increase tau aggregation propensity and disrupt its endogenous microtubule-binding activity. The structural relationship between aggregation propensity and biological activity remains unclear. We employed a multi-disciplinary approach, including computational modeling, NMR, cross-linking mass spectrometry, and cell models to design tau sequences that stabilize its structural ensemble. Our findings reveal that substitutions near the conserved ‘PGGG’ beta-turn motif can modulate local conformation, more stably engaging in interactions with the 306VQIVYK311 amyloid motif to decrease aggregation in vitro and in cells. Designed tau sequences maintain microtubule binding and explain why 3R isoforms of tau exhibit reduced pathogenesis over 4R isoforms. We propose a simple mechanism to reduce the formation of pathogenic species while preserving biological function, offering insights for therapeutic strategies aimed at reducing protein misfolding in neurodegenerative diseases.